The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Ruxolitinib for treatment of sclerotic cGvHD: Results from a phase II study
|
Sclerotic chronic graft-versus-host (cGvHD) is a highly-refractory form of cGvHD associated with high morbidity.1 The biology of sclerotic cGvHD differs to other forms of cGvHD; however, there is a lack of clinical trials investigating treatments for sclerotic cGvHD. A multicenter phase II trial assessing the efficacy and safety of ruxolitinib in 47 adult patients with sclerotic cGvHD refractory to corticosteroid and other systemic therapies was published in the Journal of Clinical Oncology by Bhatt et al.1 |
| Key learnings: |
|
At 6 months, partial response in skin and/or joints was achieved in 49% of ruxolitinib-treated patients, with 45% showing a response in joints/fascia and 19% in the skin. |
|
The overall partial response rate was 47%, with 77% of patients maintaining skin/joint response at 12 months. The failure-free survival rate at 12 months was 77.1%. |
|
38% of patients showed improvement in the Lee Symptom Scale summary and skin subscale scores, reflecting enhanced symptom management. |
|
Grade ≥3 adverse events occurred in 40% of patients, with 13% of these related to ruxolitinib. At 12 months, the cumulative incidence of non-relapse mortality and treatment failure was 2.2% and 20.8%, respectively. No cases of recurrent malignancy were observed. |
|
These findings suggest that ruxolitinib was associated with high response rates and was well tolerated, offering a promising treatment option for refractory sclerotic cGvHD. Its favorable safety and efficacy profile may support its use in earlier treatment lines and in combination with other emerging therapies. |
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
